Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- American Academy of Dermatology. Indoor tanning. Available at https://www.aad.org/media/stats/prevention-and-care
- Bareford D, Cumberbatch M, Derrick Tovey L. 1984. Plasma discolouration due to sun-tanning aids. Vox Sanguinis, 46(3):180-182.
- Beaulieu RA, et al. 2013. Canthaxanthin retinopathy with visual loss: A case report and review. Case Rep Ophthalmol Med, Article ID 40901.
- European Commission. 2010. Scientific Committee on Consumer Safety. Opinion on dihydroxyacetone. Available at https://ec.europa.eu/health/sites/default/files/scientific_committees/consumer_safety/docs/sccs_o_048.pdf
- Lapunzina P. 1996. Ultraviolet light-related neural tube defects? Am J Med Genet, 67:106.
- Meadows M. 2003. Don't be in the dark about tanning. FDA Consumer Magazine, 37:6.
- United States Food and Drug Administration. 2018. Sunless tanners and bronzers. Available at https://www.fda.gov/Cosmetics/ProductsIngredients/Products/ucm134064.htm
- United States Food and Drug Administration. 2005. Tanning Pills. Available at https://www.fda.gov/cosmetics/cosmetic-products/tanning-pills
- Yourick JJ, et al. 2004. Fate of chemicals in skin after dermal application: Does the in vitro skin reservoir affect the estimate of systemic absorption? Toxicol Appl Pharmacol, 195:309-320.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 1, 2021.

Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- Amer MR, et al. 2015. Safety of Popular Herbal Supplements in Lactating Women. J Hum Lact. 31(3):348-53.
- Ashar B H and Rowland-Seymour A. 2008, Advising Patients Who Use Dietary Supplements. Am J Med 121(2):91-7.
- Ciganda C and Laborde A. 2003, Herbal infusions used for induced abortion. J Toxicol Clin Toxicol 41(3):235-239.
- Dante G et al. 2013, Herb remedies during pregnancy: a systematic review of controlled clinical trials. J Maternal-Fetal and Neonatal Med 26(3): 306-312.
- Dante G et al. 2014, Herbal therapies in pregnancy: what works? Curr Opin Obstet Gynecol 26:83-91.
- Frawley J et al. 2015, Women's Use and Self-Prescription of Herbal Medicine during Pregnancy: An Examination of 1,835 Pregnant Women. Women's Health Issues 25-4, 396-402.
- Lei HL, et al. 2015. Relationship between risk factors for infertility in women and lead, cadmium, and arsenic blood levels: a cross-sectional study from Taiwan. BMC Public Health. 15:1220.
- Smeriglio A, et al. 2014, Herbal Products in Pregnancy: Experimental Studies and Clinical Reports. Phytother Res 28: 1107-1116.
- Trabace L, et al. 2015. "Natural" relief of pregnancy-related symptoms and neonatal outcomes: above all do no harm. J Ethnopharmacol. 174:396-402.
- Wang CC, et al. 2013, Pregnancy Outcomes, Embryonic and Fetal Development in Maternal Exposure to Chinese Medicines. Birth Defects Res (Part C) 99:275-291.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 1, 2021.

Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- Baard J, et al. 2020. The effect of beta-blockers on foetal birth weight in pregnancies in women with structural heart disease: a prospective cohort study. Cardiovasc J Afr 31(3):136-141.
- Bateman BT, et al. 2016. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics 138(3):e20160731.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 20(2):138-45.
- Firoz T, et al. 2014. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG 121(10):1210-8.
- Ruys TP,et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol 177(1):124-8.
- Semczuk M. 1987. The effects of beta-adrenergic drugs on the human sperm motility in vitro. I. The effects of propranolol and isoprenaline. Andrologia. 19 Spec No:256-61.
- Tanaka K. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 80(10):2221-6.
- Wu Y. (2021). Risk of congenital malformations in offspring of women using β-blockers during early pregnancy: An updated meta-analysis of observational studies. Br J Clin Pharmacol 87(3):806-815.
- Xie RH, et al. 2014. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 175:124-8.
- Xie RH,et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. BJOG 121(9):1090-6.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 1, 2021.

Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- Aporta RR, et al. 1998. Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient. Haematologica. 83:852-3.
- Amory, JK, et al. 2007. Miglustat has no apparent effect on spermatogenesis in normal men. Human Reproduction, ***22***(3), 702–707.
- Dornelles AD, et al. 2014. Breastfeeding in Gaucher disease: is enzyme replacement therapy safe? Clin Ther.36:990-1.
- Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol. 190(2):435-41.
- Elstein D et al. 2014. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease. J Obstet Gynaecol Res.40(4):968-975.
- Gary, Sam E. et al. Recent Advances in the Diagnosis and Management of Gaucher Disease. Expert Review of Endocrinology & Metabolism. 13(2): 107–18
- Giannubilo SR, et al. 2015. Replacement therapy for Gaucher disease during pregnancy: A case report. J Reprod Infertil 16(1): 53-57.
- Granovsky-Grisaru, S et al. 2011. The management of pregnancy in Gaucher disease. Eur I Obstet Gynecol Reprod Biol. 156: (1) 3-8.
- Komninaka V, et al. 2020. Outcomes of pregnancies in patients with Gaucher Disease: The experience of a center of excellence on rare metabolic Disease-Gaucher Disease, in Greece. Eur J Obstet Gynecol Reprod Biol. 254:181-187.
- Korkmazer E, et al. 2015. Pregnancy and lactation in a patient with Gaucher disease receiving enzyme replacement therapy: Case report. Turkey J Clin Obstet Gynecol. 25:224-6.
- Lau H, et al. 2018. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. Blood Cells Mol Dis. 68:226-231.
- Mamopoulos A M et al. 2009. Gaucher disease and pregnancy. J Obstet Gynaecol. 29: 240-242.
- Murphy E. 2015. Pregnancy in women with inherited metabolic disease. Obstet Med. 8(2): 61-67.
- Paskulin L, et al. Breastfeeding in patients with Gaucher disease: Is taliglucerase alfa safe? Molecular Genetics and Metabolism Reports, ***18***, 30–31.
- Rosenbaum H. 2015. Management of women with Gaucher disease in the reproductive age. Thromb Res. 135 Suppl 1:S49-51.
- Roy, A., et al. 2006. Shaping the sperm head: an ER enzyme leaves its mark. Journal of Clinical Investigation, 116(11), 2860–2863.
- Sekijima Y, et al. 2010. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of Imiglucerase in human breast milk. Clin Ther. 32(12): 2048-2052.
- Sherer Y, et al. 2002. Successful suc outcome in a patient with Gaucher's disease and antiphospholipid syndrome. Ann Hematol. 81:161-3.
- Stirnemann J, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. International Journal of Molecular Sciences, 18(2), 441.
- Weinreb, N. J. 2008. Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opinion on Pharmacotherapy, 9(11), 1987–2000.
- Zimran A, et al. 2009. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events. Blood Cells Mol Dis. 43:264-288.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 1, 2021.

Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- Berle JO, et al. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. J Clin Psychiatry 65:1228-34. PMID: 15367050
- Brunel P, et al. 1994. [Follow-up of 151 pregnant women exposed to antidepressant treatment (MAOI excluded) during organogenesis.] Therapie 49:117-122.
- Eggermont E. 1973. Withdrawal symptoms in neonate associated with maternal imipramine therapy. Lancet 2:680.
- Misri S & Sivertz K. 1991. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 21(2):157-71.
- Mitchell JE and Popkin MK: Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharm 3:76-79, 1983.
- Nulman I, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258-62.
- Overo KF, et al. 1997. Interaction of perphenazine with the kinetics of nortriptyline. Acta Pharmacol Toxicol; 40:97-105.
- Shearer WT, et al. 1972. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 81:570-2.
- Schoretsanitis S, et al. 2020. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol; 16(5):431-440.
- US Preventive Services Task Force, Curry SJ, et al. 2019. Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. JAMA 321(6):580-587.
- Webster PA. 1973. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 2(7824):318-9.
- Weissman AM, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 161:1066-78. PMID: 15169695
- Wisner KL, et al. 2002. Postpartum depression. N Engl J Med. 347:194-9. PMID: 12124409.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 1, 2021.